Mutations in oncogenes, such as KRAS [44]; and subsets of loss-of-function mutations in tumor suppressors, such as FBXW7 [34, 45] or STK11 [46], can cause resistance to DNA damage based therapies. This evidence concerns the gene KRAS and neoplasm.